Dendreon Rebounds In Q4 2011, But Can It Keep It Up In 2012?

The biotech reported gross product revenue for Provenge of approximately $82 million in Q4 2011, better than doubling Q4 2010 sales. Management credits improved reimbursement dynamics and sales execution.